• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医院环境之外的 SARS-CoV-2 疫苗接种的医疗事件和安全性。

Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting.

机构信息

Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.

Department of Pathophysiology and Transplantation, University of Milan, Padiglione Litta, Milan, Italy.

出版信息

Intern Emerg Med. 2024 Sep;19(6):1593-1604. doi: 10.1007/s11739-024-03641-4. Epub 2024 Jul 23.

DOI:10.1007/s11739-024-03641-4
PMID:39042210
Abstract

During COVID-19 pandemic, vaccination has been strongly recommended and advocated to prevent COVID-19 infection and adverse outcomes, particularly among at-risk populations. The vaccination against SARS-CoV-2 (COVAC) occurred at off-site locations capable of accommodating large crowds, distinct from the hospital setting, where a team of intensivists, emergency physicians, and nurses, ensuring prompt medical attention (medical occurrences, MO) in cases of adverse event following immunization. Our aims were to estimate the incidence of MO, and to assess its association with demographics, and vaccine characteristics. Our retrospective cohort study included all subject aged 12 years and older who received vaccinations at two large out-of-hospital vaccination hubs (Fiera Milano City, Palazzo delle Scintille), between April 12th and August 31st, 2021. Nine hundred and ninety-five thousand and twenty-eight vaccinations were administrated. MOs incidence rate was 278/100,000 doses (95% confidence interval (CI) 268-289). Most MOs were mild (86.27%) and mainly observed in subjects who received the Comirnaty vaccine; 92 MOs (3.32%) were severe and mostly occurred in recipients of the Vaxzeria vaccine. The incidence rate for hospital transfers following vaccination was 4.7/100,000 doses (95% CI 3.5-6.2) and any level of anaphylaxis occurred in 0.4 cases per 100,000 administrated doses (95% CI 0.3.-0.7). Sex, age, type of vaccine and first dose were associated with incidence of MO. Our results showed a low incidence rate in MOs after COVAC, mainly mild and support the feasibility, effectiveness and safety of vaccinations administered in hubs with a dedicated SEU located outside of the hospital setting.

摘要

在 COVID-19 大流行期间,强烈建议和提倡接种疫苗以预防 COVID-19 感染和不良后果,特别是在高危人群中。针对 SARS-CoV-2(COVAC)的疫苗接种是在能够容纳大量人群的场外地点进行的,与医院环境不同,那里有一组重症监护医生、急诊医生和护士,以确保在接种后出现不良事件时能得到及时的医疗关注(医疗事件,MO)。我们的目的是估计 MO 的发生率,并评估其与人口统计学和疫苗特征的关联。我们的回顾性队列研究包括 2021 年 4 月 12 日至 8 月 31 日期间在两个大型场外疫苗接种中心(米兰会展城,Palazzo delle Scintille)接受疫苗接种的所有年龄在 12 岁及以上的受试者。共接种了 995 万 2800 剂疫苗。MO 发生率为 278/100,000 剂(95%置信区间(CI)268-289)。大多数 MO 是轻度的(86.27%),主要发生在接受 Comirnaty 疫苗的受试者中;92 例 MO(3.32%)为重度,主要发生在接受 Vaxzeria 疫苗的受试者中。接种疫苗后住院转移的发生率为 4.7/100,000 剂(95%CI 3.5-6.2),每 100,000 剂中发生任何程度过敏反应的比例为 0.4 例(95%CI 0.3.-0.7)。性别、年龄、疫苗类型和首剂与 MO 发生率相关。我们的结果显示 COVAC 后 MO 发生率较低,主要为轻度,支持在远离医院环境的专门 SEU 场外地点接种疫苗的可行性、有效性和安全性。

相似文献

1
Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting.医院环境之外的 SARS-CoV-2 疫苗接种的医疗事件和安全性。
Intern Emerg Med. 2024 Sep;19(6):1593-1604. doi: 10.1007/s11739-024-03641-4. Epub 2024 Jul 23.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.香港接种 mRNA(BNT162b2)和灭活(科兴)SARS-CoV-2 疫苗后特殊关注的不良事件和死亡率:一项回顾性研究。
PLoS Med. 2022 Jun 21;19(6):e1004018. doi: 10.1371/journal.pmed.1004018. eCollection 2022 Jun.
4
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.在意大利德尔塔变异株流行期间,mRNA 疫苗对 SARS-CoV-2 感染和重症 COVID-19 的有效性及其保护作用的衰减:回顾性队列研究。
BMJ. 2022 Feb 10;376:e069052. doi: 10.1136/bmj-2021-069052.
5
An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.一项针对风湿和免疫介导性疾病患者的阿根廷队列研究:SARS-CoV-2 疫苗接种:SAR-CoVAC 注册研究方案和初步数据。
Clin Rheumatol. 2022 Oct;41(10):3199-3209. doi: 10.1007/s10067-022-06253-5. Epub 2022 Jun 28.
6
Setting up and managing the largest COVID-19 mass vaccination center in Lombardy, Italy.在意大利伦巴第大区设立和管理最大的 COVID-19 大规模疫苗接种中心。
Front Public Health. 2023 Nov 17;11:1290350. doi: 10.3389/fpubh.2023.1290350. eCollection 2023.
7
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后,mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果:一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
8
COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study.德国 COVID-19 疫苗有效性和数字大流行监测(eCOV 研究):基于网络应用的前瞻性观察队列研究。
J Med Internet Res. 2024 Jun 4;26:e47070. doi: 10.2196/47070.
9
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
10
Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.加拿大安大略省青少年和成年人中,基于疫苗产品、接种程序和剂间间隔的 mRNA 疫苗接种后心肌炎和心包炎的流行病学。
JAMA Netw Open. 2022 Jun 1;5(6):e2218505. doi: 10.1001/jamanetworkopen.2022.18505.

本文引用的文献

1
Familial Hypercholesterolemia: A Literature Review of the Pathophysiology and Current and Novel Treatments.家族性高胆固醇血症:病理生理学以及当前和新型治疗方法的文献综述
Cureus. 2023 Nov 20;15(11):e49121. doi: 10.7759/cureus.49121. eCollection 2023 Nov.
2
Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers.韩国医护人员接种第三剂 BNT162b2 mRNA COVID-19 疫苗的不良事件。
Medicine (Baltimore). 2023 Mar 17;102(11):e33236. doi: 10.1097/MD.0000000000033236.
3
Efficacy and Short-Term Safety of COVID-19 Vaccines: A Cross-Sectional Study on Vaccinated People in the UAE.
新冠疫苗的疗效与短期安全性:阿联酋接种者的横断面研究
Vaccines (Basel). 2022 Dec 15;10(12):2157. doi: 10.3390/vaccines10122157.
4
Anaphylaxis is rare due to CoronaVac in a population of healthcare workers.在医护人员群体中,科兴新冠疫苗引起过敏反应的情况很罕见。
Asia Pac Allergy. 2022 Oct 17;12(4):e35. doi: 10.5415/apallergy.2022.12.e35. eCollection 2022 Oct.
5
Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy.意大利伦巴第地区 COVID-19 疫苗接种与入住重症监护病房以及 COVID-19 肺炎重症患者结局的相关性。
JAMA Netw Open. 2022 Oct 3;5(10):e2238871. doi: 10.1001/jamanetworkopen.2022.38871.
6
Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study.非洲埃塞俄比亚医护人员报告的牛津阿斯利康 COVID-19 疫苗的副作用:一项横断面研究。
Front Public Health. 2022 Jul 19;10:937794. doi: 10.3389/fpubh.2022.937794. eCollection 2022.
7
Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine.辉瑞-BioNTech新冠疫苗接种后不良事件的性别差异
Vaccines (Basel). 2022 Feb 3;10(2):233. doi: 10.3390/vaccines10020233.
8
Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study.在日本,年龄、性别和病史对 BNT162b2 mRNA COVID-19 疫苗第一和第二剂不良反应的影响:一项横断面研究。
BMC Infect Dis. 2022 Feb 23;22(1):179. doi: 10.1186/s12879-022-07175-y.
9
Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.日本对 BNT162b2 和 mRNA-1273 mRNA COVID-19 疫苗的不良反应。
J Infect Chemother. 2022 Apr;28(4):576-581. doi: 10.1016/j.jiac.2021.12.034. Epub 2022 Jan 11.
10
Post-vaccination survey for monitoring the side effects associated with COVID-19 vaccines among healthcare professionals of Jazan province, Saudi Arabia.沙特阿拉伯吉赞省医护人员接种 COVID-19 疫苗后不良反应监测的问卷调查。
Saudi Med J. 2021 Dec;42(12):1341-1352. doi: 10.15537/smj.2021.42.12.20210576.